It may only be a matter of time until expectant mothers can monitor the heartbeats of their unborn child from home with medtech company HeraMed (ASX: HMD) pursuing regulatory reclassification to enable their HeraBEAT device to be reinstated for commercial distribution. HeraMED is advancing discussions with the Therapeutic Goods Administration (TGA) to reinstate its HeraBEAT
Read More
With the rapid acceleration of telehealth solutions brought about by the pandemic, one company is uniquely servicing a key demographic- expectant mothers. Medtech HeraMED (ASX: HMD) is moving obstetric care into 2021 with their comprehensive digital health platform, HeraCARE and associated fetal and maternal heart rate monitor, HeraBEAT. The clinically validated tech allows for remote
Read More
Medical data and technology company HeraMED (ASX: HMD) has today announced a partnership to accelerate their mission to revolutionise maternal care. The Company has entered into a paid pilot with Obstetrix Medical Group, one of the largest clinical providers in the US for both women’s and children’s health. Obstetrix, an affiliate of US $2.2 billion
Read More
Bringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which
Read More
Prior to COVID-19 bringing attention to the value of telehealth, HeraMED (ASX: HMD) has been building digital infrastructure to revolutionise the maternal healthcare market with their screening and remote midwife platform which is preparing to now enter the lucrative U.S market. The expansion into the world’s most lucrative healthcare market, valued at USD $111 billion
Read More
Medtech company HeraMED (ASX: HMD) has seen a major spike in investor confidence after securing clearance from the US Food and Drug Administration (FDA) for HeraBEAT US – their fetal ultrasonic heart monitor. Intended to detect, display and replay heart beats from as early as 12 weeks into pregnancy, the handheld device was developed in
Read More